Navigation Links
Revealed:Protein's role in preventing heart muscle growth leading to heart failure
Date:5/12/2014

Cardiovascular disease remains the number one cause of death in the Western world, with heart failure representing the fastest-growing subclass over the past decade. The stage that precedes heart failure in a significant number of cardiovascular diseases is pathological hypertrophy the growth of the heart muscle in an attempt to increase its output.

Not all hypertrophy is pathological; for example, during pregnancy or high physical exertion, the muscle of the heart grows but myocardial function remains normal. But when hypertrophy is excessive, prolonged and unbalanced, it becomes pathological, leading to heart failure and arrhythmias.

Now for the first time, researchers at the Hebrew University of Jerusalem's Faculty of Medicine have revealed how a protein called Erbin acts as a brake against this excessive and pathological growth of heart muscle. They also demonstrated that damage to this protein leads to excess growth of heart muscle, a decrease in function, and severe pathological growth of heart muscle.

The research was conducted by Ms. Inbal Rachmin as part of her doctoral thesis, under the supervision of Prof. Ehud Razin and Dr. Sagi Tshori at the Institute for Medical Research IsraelCanada in the Faculty of Medicine at the Hebrew University of Jerusalem. The study, "Erbin is a negative modulator of cardiac hypertrophy," was published in the Proceedings of the National Academy of Sciences (PNAS).

Ms. Rachmin detected a significant decrease in the expression of the protein Erbin in the heart tissue of patients suffering from heart failure. Moreover, the induction of hypertrophy in mice lacking Erbin led to the early death all of these mice, compared to only about 30 percent mortality observed in the control group. Histological examination showed that heart failure was the main reason for this.

This important research also has further implications in the area of breast cancer treatment. Erbin interacts with the receptor Her2/ErBb2, which is overexpressed in approximately 30% of breast cancers. The standard treatment in these cases is the use of Herceptin, an antibody to this receptor. Studies have shown that 5-10 percent of breast cancer patients who received this treatment together with chemotherapy have a significant decrease in heart function. The researchers describe a cardioprotective role for Erbin, which suggests it is a potential target for cardiac gene therapy.


'/>"/>

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-82844
The Hebrew University of Jerusalem
Source:Eurekalert

Related medicine news :

1. New clues found to preventing lung transplant rejection
2. National plan for preventing healthcare-associated infections shows progress
3. New study shows promise for preventing therapy resistance in tumor cells
4. LA BioMed study finds daily antibiotics most effective in preventing recurrent urinary tract infection
5. Preventing Outdoor Decks From Failing
6. UV Technologies, LLC, Makers of UV-Aid® Release Results of Study Showing Photo-Oxidation Technology Highly Effective in Preventing Colds, Flu, and Ear Infections
7. Life Insurance for Seniors and the Importance of Preventing Chronic Diseases
8. Tips for Preventing Kitchen Hassles Released in New Article from Apollo Plumbing
9. Top hospitals reduce readmissions by preventing complications across all diagnoses
10. Edoxaban effective in preventing stroke, reducing bleeding and cardiovascular death in patients with atrial fibrillation
11. Seven Helpful Tips For Preventing Back Pain In Those With Sedentary Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... , ... Bellus Medical, a leader in medical aesthetics, recently ... of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated ... and minimize the appearance of pores – all with minimal downtime and results ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... ... Lake Park Dental is now accepting new patients with crooked teeth who ... the help of this highly-effective, yet convenient system, patients can straighten their teeth and ... pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America (BPC), ... reputable physician in their area, announces the launch of a new and proprietary customer ... are looking for reputable physicians to help them with back or neck pain and ...
(Date:4/25/2017)... Ariz. (PRWEB) , ... April 25, 2017 , ... Emergency ... latest book of the Outlier Leadership Series, Outliers in Writing, set to publish in ... Professor of Emergency Medicine at the University of Arizona College of Medicine. He also ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: